Advertisement

Search Results

Advertisement



Your search for 3 matches 14920 pages

Showing 1201 - 1250


integrative oncology

Understanding Patient Engagement in Virtual Mind-Body Therapies

Guest Editor’s Note: Virtual platforms have grown increasingly popular for health- and wellness-promoting activities. But given patients’ unique backgrounds, capabilities, interests, and goals, promoting engagement represents a complex challenge both in the context of care delivery as well as...

gastroesophageal cancer
gastrointestinal cancer

Novel Antibody-Drug Conjugate Shows Potential in Treating CLDN18.2-Positive Gastric and GEJ Cancers

A first-in-class, claudin 18.2 (CLDN18.2)-targeted antibody-drug conjugate may be a new treatment option for patients with advanced gastric/gastroesophageal junction (GEJ) cancers, according to data presented by Xu et al during the ASCO Plenary Series: November 2023 Session (Abstract 434420)....

prostate cancer

Metastatic Castration-Resistant Prostate Cancer: Single-Dose LuPSMA Plus Maintenance Pembrolizumab

In a single-institution phase I dose-expansion trial reported in The Lancet Oncology, Aggarwal et al found that a single dose of lutetium-177–PSMA-617 (LuPSMA) followed by pembrolizumab maintenance was associated with activity in patients with metastatic castration-resistant prostate cancer. Study...

gastroesophageal cancer
gastrointestinal cancer

Adding Pembrolizumab to Trastuzumab and Chemotherapy in HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma: KEYNOTE-811

In interim analyses from the phase III KEYNOTE-811 trial reported in The Lancet, Yelena Y. Janjigian, MD, and colleagues found that the addition of pembrolizumab to trastuzumab and chemotherapy in first-line treatment of patients with locally advanced or metastatic HER2-positive...

leukemia
lymphoma
hematologic malignancies

Nemtabrutinib May Provide Benefit in Patients With Relapsed Hematologic Malignancies

The BTK inhibitor nemtabrutinib may offer a new treatment option for patients with relapsed hematologic malignancies such as chronic lymphocytic leukemia and non-Hodgkin lymphoma, according to a recent study published by Woyach et al in Cancer Discovery. Background Hematologic malignancies are...

hepatobiliary cancer

Adjuvant Atezolizumab/Bevacizumab vs Active Surveillance in Resected or Ablated High-Risk Hepatocellular Carcinoma

As reported in The Lancet by Shukui Qin, MD, and colleagues, interim analysis of the phase III IMbrave050 trial has shown significantly better recurrence-free survival with adjuvant atezolizumab/bevacizumab vs active surveillance in patients who underwent curative-intent resection or ablation for...

gastrointestinal cancer

Adding HIPEC to Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases

As reported in the Journal of Clinical Oncology by Rau et al, the German phase III GASTRIPEC-I trial showed no improvement in overall survival with the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery in patients with gastric cancer and synchronous peritoneal...

gynecologic cancers

Addition of First-Line Pembrolizumab to Chemotherapy, With or Without Bevacizumab, in Advanced Cervical Cancer: Final Overall Survival Results From KEYNOTE-826

In an analysis reported in the Journal of Clinical Oncology, Bradley J. Monk, MD, FACS, FACOG, and colleagues described final overall survival results from the phase III KEYNOTE-826 trial, which evaluated the addition of first-line pembrolizumab to chemotherapy, with or without bevacizumab, in...

lung cancer

First-Line Selpercatinib vs Chemotherapy With or Without Pembrolizumab in RET Fusion–Positive NSCLC

An interim analysis of the phase III LIBRETTO-431 trial has shown significantly improved progression-free survival with first-line selpercatinib vs platinum-based chemotherapy with or without pembrolizumab in patients with RET fusion–positive advanced non–small cell lung cancer (NSCLC). The...

lung cancer

Bispecific T-Cell Engager Tarlatamab in Previously Treated Patients With Small Cell Lung Cancer

In the phase II DeLLphi-301 trial—presented at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract LBA92) and reported by Ahn et al in The New England Journal of Medicine—tarlatamab, a bispecific T-cell engager targeting delta-like ligand 3 and CD3, exhibited activity in...

lung cancer
immunotherapy

Perioperative Durvalumab in Resectable NSCLC: AEGEAN Trial

As reported in The New England Journal of Medicine by John V. Heymach, MD, PhD, and colleagues, the phase III AEGEAN trial has shown that perioperative durvalumab improved event-free survival and pathologic complete response (pCR) rate in patients with resectable non–small cell lung cancer ...

solid tumors
issues in oncology

Novel Blood Test May Offer Early Cancer Detection

Researchers have developed a highly sensitive blood test capable of early detection by identifying a key protein produced by cancer cells, according to a novel study published by Taylor et al in Cancer Discovery. Background Many tumors become deadly by remaining asymptomatic until they’re too...

gastroesophageal cancer
gastrointestinal cancer
immunotherapy

Addition of First-Line Pembrolizumab to Chemotherapy in HER2-Negative Advanced Gastric Cancer

As reported in The Lancet Oncology by Sun Young Rha, MD, and colleagues, the phase III KEYNOTE-859 trial has shown that the addition of first-line pembrolizumab to chemotherapy was associated with a statistically significant improvement  in overall survival in patients with HER2-negative advanced...

issues in oncology
global cancer care

International Group of Surgical Oncologists Presents New Commission Outlining Pragmatic Solutions to Improve Cancer Surgery Outcomes Worldwide

Building upon recommendations from the 2015 Lancet Oncology Global Cancer Surgery Commission, a new Commission report aims to provide a pragmatic roadmap for decision-makers to reduce inequities and promote safe, timely, and affordable cancer surgery for every patient. The Commission report was...

thyroid cancer

Advanced RET-Mutant Medullary Thyroid Cancer: First-Line Selpercatinib

As presented at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract LBA3) and reported in The New England Journal of Medicine by Hadoux et al, an interim analysis from the phase III LIBRETTO-531 trial has shown improved progression-free survival with selpercatinib vs...

skin cancer

3-Year Overall Survival With Tebentafusp in Previously Untreated Advanced Uveal Melanoma

In an analysis presented at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract LBA50) and reported in The New England Journal of Medicine by Jessica C. Hassel, MD, and colleagues, overall survival at 3 years in the phase III IMCgp100-202 trial continued to favor...

hepatobiliary cancer
immunotherapy

FDA Approves Pembrolizumab Plus Chemotherapy for Biliary Tract Cancer

On October 31, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) to be used with gemcitabine and cisplatin for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. KEYNOTE-966 Efficacy was evaluated in KEYNOTE-966...

leukemia
issues in oncology
global cancer care

Expanded Soy Production in Brazil May Be Linked to Increased Mortality Among Pediatric Patients With ALL

Researchers have reported that soy expansion and the subsequent increase of pesticide use in Brazil’s Cerrado and Amazon biomes may correlate with an increased risk of mortality among pediatric patients with acute lymphoblastic leukemia (ALL). The study was published by Skidmore et al in...

lung cancer
genomics/genetics

Addition of Amivantamab to Chemotherapy in First-Line Treatment of Advanced NSCLC With EGFR Exon 20 Insertions

The phase III PAPILLON study has shown that the addition of amivantamab-vmjw to chemotherapy significantly improved progression-free survival in the first-line treatment of advanced non–small cell lung cancer (NSCLC) with EGFR exon 20 insertions. The findings were presented at the European Society...

lung cancer
skin cancer
cost of care

Patients With Newly Diagnosed NSCLC or Melanoma May Receive Limited Documentation of Treatment Cost Discussions

Investigators have uncovered that only about 25% of patients newly diagnosed with advanced cancer have documented physician discussions about the costs of care, which may make it more difficult to identify patient needs and track the outcomes of referrals for assistance, according to new findings...

kidney cancer
immunotherapy

Nivolumab With or Without Nivolumab/Ipilimumab Boost in Metastatic Renal Cell Carcinoma

In the phase II TITAN-RCC trial reported in The Lancet Oncology, Grimm et al found that a strategy of nivolumab monotherapy with or without nivolumab/ipilimumab as an immunotherapeutic boost was associated with activity in patients with metastatic clear cell renal cell carcinoma. Study Details In...

colorectal cancer

Sotorasib Plus Panitumumab in KRAS G12C–Mutated Advanced Colorectal Cancer: CodeBreaK 300

The phase III CodeBreaK 300 trial showed that sotorasib plus panitumumab improved progression-free survival vs standard care in patients with KRAS G12C–mutated refractory metastatic colorectal cancer. Findings were presented at the European Society for Medical Oncology (ESMO) Congress 2023 (LBA10)...

cardio-oncology

Cardiovascular Disease and Cancer: A Reciprocal Relationship?

More attention is being paid to the topic of cardio-oncology, where the focus is on patients with cancer who may be at risk for developing cardiovascular diseases as a result of anticancer treatments. However, a less well-known but related clinical area is now garnering some interest. Referred to...

kidney cancer

Stereotactic Body Radiation Therapy Demonstrates ‘Exceptional Control’ in Primary Renal Cell Carcinoma

Although surgery remains the standard of care for primary renal cell carcinoma, a novel, noninvasive approach has yielded positive results that could pave the way for future treatment strategies, according to data presented at the 2023 American Society for Radiation Oncology (ASTRO) Annual...

prostate cancer

PACE Trials Support Stereotactic Body Radiotherapy for Some Patients With Localized Prostate Cancer

Prostate cancer treatment just got a major boost from the PACE trials, which may have established a new standard of care in low- and favorable intermediate-risk disease, according to data presented at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 The results of the phase ...

lung cancer

Perioperative Nivolumab Plus Chemotherapy Improves Event-Free Survival in Resectable Non–Small Cell Lung Cancer

A perioperative regimen of neoadjuvant nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab achieved a statistically significant and clinically meaningful improvement in event-free survival compared with neoadjuvant chemotherapy plus placebo followed by surgery and adjuvant...

head and neck cancer

FDA Approves Toripalimab-tpzi for Nasopharyngeal Carcinoma

On October 27, the U.S. Food and Drug Administration (FDA) approved toripalimab-tpzi (Loqtorz) with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma. The FDA also approved toripalimab-tpzi as a single agent for...

leukemia
immunotherapy

Sequential CD19- and CD22-Directed CAR T-Cell Therapy in Pediatric B-Cell ALL

In a Chinese single-center phase II study reported in The Lancet Oncology, Pan et al found that sequential CD19- and CD22-directed chimeric antigen receptor (CAR) T-cell therapy was active in pediatric patients with refractory or relapsed B-cell acute lymphocytic leukemia (ALL). Study Details In...

prostate cancer

Enzalutamide With or Without Leuprolide and Leuprolide Alone in Biochemically Recurrent Prostate Cancer

In the phase III EMBARK trial reported in The New England Journal of Medicine, Stephen J. Freedland, MD, and colleagues found that enzalutamide/leuprolide and enzalutamide alone improved metastasis-free survival vs leuprolide alone in patients with high-risk biochemical recurrence of prostate...

lung cancer

Pembrolizumab Plus Lenvatinib as Second- and Third-Line Treatments of Pleural Mesothelioma

In a Dutch single-institution phase II trial (PEMMELA) reported in The Lancet Oncology, Douma et al found that the combination of pembrolizumab and lenvatinib showed activity as second- and third-line treatments of patients with pleural mesothelioma. Study Details A total of 38 evaluable patients...

ASCO Launches ‘ASCO Certified’ to Ensure the Delivery of High-Quality, Patient-Centered Cancer Care to Every Patient

On October 25, 2023, ASCO announced the launch of its new flagship quality program ASCO Certified™, with the goal of ensuring that every patient with cancer has access to high-quality, patient-centered, coordinated cancer care.1 The program, which officially launched on October 27, 2023, to...

breast cancer

Early Triple-Negative Breast Cancer

This is Part 3 of Updates in Early-Stage Breast Cancer,, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable.   In this video, Drs. Erika Hamilton, Michael Danso, and Komal Jhaveri discuss the management of early triple-negative breast cancer. The...

breast cancer

Early Hormone Receptor–Positive/HER2-Negative Breast Cancer

This is Part 1 of Updates in Early-Stage Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable.   In this video, Drs. Erika Hamilton, Michael Danso, and Komal Jhaveri discuss the management of early hormone receptor–positive/HER2-negative...

head and neck cancer
supportive care

Yoga-Based Supportive Care May Prevent Treatment-Related Complications in Patients With Head and Neck Cancer

Yoga-based supportive care may help alleviate the negative side effects of radiation treatment, decrease the use of feeding tube placements, and reduce emergency department visits in patients with head and neck cancer, especially when family caregivers participate, according to new findings...

gastroesophageal cancer
gastrointestinal cancer

Perioperative Chemotherapy and Pembrolizumab in Locally Advanced Resectable Gastric and Gastroesophageal Junction Adenocarcinomas

In a phase II trial reported in JAMA Oncology, Manji et al found that perioperative chemotherapy and pembrolizumab showed activity in locally advanced resectable gastric and gastroesophageal junction adenocarcinoma. Study Details Thirty-four evaluable patients were enrolled in the...

issues in oncology

Primary Care Intervention to Improve Follow-up of Overdue Abnormal Cancer Screening Test Results

In a study reported in JAMA, Atlas et al found that a primary care intervention including electronic health record (EHR) reminders and patient outreach with or without patient navigation improved timeliness of follow-up of overdue abnormal cancer screening test results. Study Details The open-label ...

issues in oncology

Overcoming the Challenges of Treating Adolescents and Young Adults With Cancer Living in Rural Communities

It is widely acknowledged that patients with cancer living in rural areas of the United States face limited access to medical and oncology providers, often have to travel long distances to receive care, and experience obstacles in clinical trial participation—all of which affect quality of care and ...

lung cancer

Comparing Two Radiation Therapy Techniques for Locally Advanced NSCLC: Focus on Toxicity

Intensity-modulated radiation therapy (IMRT) reduced the risk of toxicity to the lungs and radiation exposure to the heart vs three-dimensional conformal radiotherapy (3D-CRT) for the treatment of locally advanced non–small cell lung cancer (NSCLC), according to a planned long-term prospective...

lung cancer
immunotherapy

Role of TROP-2–Directed Antibody-Drug Conjugates With Immune Checkpoint Inhibitors in Advanced NSCLC

Early-phase trials demonstrate the potential for TROP-2–directed antibody-drug conjugates to enhance the response to immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC) without actionable genomic alterations, several investigators reported at the International...

hematologic malignancies
issues in oncology

Gender Equity in Academic Hematology: Where There’s a ‘WiL,’ There’s a Way

Gender diversity, equity, and inclusion (DEI) in medicine has long been acknowledged as more than “the right thing to do,” with clear evidence of benefits in innovation, collaboration, and workplace culture.1 Yet the data continue to showcase challenges in achieving these goals despite women...

leukemia

Getting a Cancer Diagnosis at Age 16 Has Taught Me to Live in the Present

I have been fascinated with death since I was 3 years old. I remember going to my great-grandfather’s funeral and asking my mother where my great-grandfather was. She said he is in heaven. I asked her if I were going to heaven, too, and she said, “Yes, but not for a long time.” Today, I don’t...

Breakthrough Prize, ‘Oscars of Science,’ Celebrates 2024 Laureates in Life Sciences

On September 14, 2023, the Breakthrough Prize Foundation announced the winners of the 2024 awards, honoring an esteemed group of the world’s researchers for their impactful scientific discoveries, including a subset responsible for substantial progress in the understanding and treatment of major...

global cancer care

From Humble Beginnings, Elisabete Weiderpass, MD, MSc, PhD, Distinguishes Herself as First Woman to Head the IARC

In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Elisabete Weiderpass, MD, MSc, PhD, a Brazilian cancer researcher who is a naturalized Swedish and Finnish citizen. She is an expert in cancer epidemiology and cancer prevention. In...

Expert Point of View: Helena Linardou, MD, PhD

Helena Linardou, MD, PhD, Director of the 4th Department of Oncology and the Comprehensive Clinical Trials Center, Metropolitan Hospital, Athens, served as discussant of the session on antibody-drug conjugates at the 2023 World Conference on Lung Cancer. Calling antibody-drug conjugates “the next...

lung cancer

HERTHENA-Lung01: Antitumor Activity Shown With HER3-DXd in EGFR-Mutated NSCLC

The treatment of patients with epidermal growth factor receptor (EGFR)-mutated lung cancer that progresses on EGFR-targeted tyrosine kinase inhibitors has been challenging. In the phase II HERTHENA-Lung01 trial, the topoisomerase-1 HER3-targeting antibody-drug conjugate patritumab deruxtecan...

prostate cancer

PSMAfore: Lutetium Lu-177 Vipivotide Tetraxetan in Metastatic Prostate Cancer

Data from the phase III PSMAfore trial were presented during a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract LBA13). Results showed that the trial of lutetium Lu-177 vipivotide tetraxetan met its primary endpoint, with a clinically meaningful and ...

bladder cancer
immunotherapy

Nivolumab Plus Gemcitabine and Cisplatin May Improve Survival in Patients With Metastatic Urothelial Carcinoma

Researchers have found that nivolumab in combination with a chemotherapy regimen may improve the rate of survival in patients with metastatic urothelial carcinoma, according to new findings simultaneously published by van der Heijden et al in The New England Journal of Medicine and presented at the ...

neuroendocrine tumors

Cabozantinib for Pretreated Patients With Advanced Neuroendocrine Tumors: CABINET Trial

The Alliance for Clinical Trials in Oncology announced detailed results from CABINET (Alliance A021602), a phase III pivotal trial evaluating cabozantinib compared with placebo in two cohorts of previously treated patients with neuroendocrine tumors. The data were presented by Chan et al at the...

bladder cancer

Erdafitinib Demonstrates Improved Responses in FGFR-Altered Advanced Urothelial Carcinoma

Targeted treatment with the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib improved responses and overall survival compared to standard chemotherapy for patients with advanced or metastatic urothelial carcinoma with FGFR alterations. Results from the phase III THOR trial, led by...

skin cancer

ESMO 2023: New Data in Skin Cancers

At the European Society for Medical Oncology (ESMO) Congress 2023, new findings are being presented in cutaneous squamous cell carcinoma, late-stage melanoma, and refractory melanoma brain metastases. Presurgical Immunotherapy in Advanced Operable Cutaneous Squamous Cell Carcinoma Patients with...

Advertisement

Advertisement




Advertisement